Literature DB >> 2867490

CSF cyclic nucleotides and somatostatin in Parkinson's disease.

L Volicer, M F Beal, L K Direnfeld, J K Marquis, M L Albert.   

Abstract

Concentrations of cyclic adenosine 3',5' monophosphate (cAMP) were significantly lower in parkinsonian patients than in controls, but concentrations of guanosine 3',5' monophosphate (cGMP) were not altered. Both cAMP and cGMP levels were lower in patients with more severe symptoms on the left side of the body. Somatostatin-like immunoreactivity (SLI) was similar in parkinsonian patients and controls. Both cAMP and SLI were significantly related to acetylcholinesterase activity.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2867490     DOI： 10.1212/wnl.36.1.89

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  8 in total

1.  Dopamine Deficiency Reduces Striatal Cholinergic Interneuron Function in Models of Parkinson's Disease.

Authors:  Jonathan W McKinley; Ziqing Shi; Ivana Kawikova; Matthew Hur; Ian J Bamford; Suma Priya Sudarsana Devi; Annie Vahedipour; Martin Darvas; Nigel S Bamford
Journal:  Neuron       Date:  2019-07-16       Impact factor: 17.173

Review 2.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

3.  Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors.

Authors:  P Hartikainen; H Soininen; K J Reinikainen; J Sirviö; R Soikkeli; P J Riekkinen
Journal:  J Neural Transm Gen Sect       Date:  1991

4.  CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Patrick Oeckl; Petra Steinacker; Stefan Lehnert; Sarah Jesse; Hans A Kretzschmar; Albert C Ludolph; Markus Otto; Boris Ferger
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

Review 5.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

6.  Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression.

Authors:  Raphael Hesse; Ludwig Lausser; Pauline Gummert; Florian Schmid; Anke Wahler; Cathrin Schnack; Katja S Kroker; Markus Otto; Hayrettin Tumani; Hans A Kestler; Holger Rosenbrock; Christine A F von Arnim
Journal:  Alzheimers Res Ther       Date:  2017-03-09       Impact factor: 6.982

Review 7.  Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.

Authors:  Karin D van Dijk; Charlotte E Teunissen; Benjamin Drukarch; Connie R Jimenez; Henk J Groenewegen; Henk W Berendse; Wilma D J van de Berg
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

8.  Phosphodiesterase Inhibition and Regulation of Dopaminergic Frontal and Striatal Functioning: Clinical Implications.

Authors:  Pim R A Heckman; Marlies A van Duinen; Eva P P Bollen; Akinori Nishi; Lawrence P Wennogle; Arjan Blokland; Jos Prickaerts
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-02       Impact factor: 5.176
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.